Anavex Life Sciences Corp.

NASDAQ:AVXL

Biotechnology

Healthcare
$0.72 -1.67%

-$0.04 today

Market cap
$66.69M
Beta
1.12
P/E (TTM)
-5.9
EPS (TTM)
-$0.45
52W Low $2.41High $13.99

Volume 1.06M

Average 1.39M

AVXL Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Anavex Life Sciences Corp.NASDAQ: AVXL

Accounts Receivables · Q1 FY2026 · quarter ended Dec 2025

Accounts receivables dips below year-ago levels

Q1 FY2026 accounts receivables of $35K (cash outflow) fell 67.6% year over year, behind the +72.7% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at -34.9% a year.

Context

  • Accounts receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -67.6% toward the trailing-twelve-month pace of +72.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-$35K-418.2% QoQ
Last fiscal yearSep 2025
$1.64M+530.8% YoY
LTMDec 2025
$1.71M+72.7% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-67.6%——
1 year+530.8%——
3-year CAGR-34.9%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
1.64M USD
Year-over-year change
+530.8%

Accounts Receivables vs competitors

How AVXL compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +72.7% is the 5th highest of 8, against a peer median of +100.0%.
  • Over three fiscal years its annual growth of -34.9% compares with a peer median of +2.4%.
AVXL Competitors
Accounts Receivables for AVXL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGTXMeiraGTx Holdings plcLTM Mar 2026$13.03M USD-178.8%—16.3%
RGNXREGENXBIO Inc.LTM Mar 2026$9.02M USD+328.9%—10.3%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$2.07M USD+38.7%+209.4%—
ARVNArvinas, Inc.LTM Mar 2026$2M USD+253.8%-19.5%2.2%
AVXLAnavex Life Sciences Corp.LTM Dec 2025$1.71M USD+72.7%-34.9%—
ABSIAbsci CorporationLTM Mar 2026$1.38M USD+207.1%—75.4%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$1.31M USD-88.3%—3.7%
ERASErasca, Inc.LTM Sep 2026$0 USD———
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$0 USD———
VALNValneva SELTM Mar 2026€0 EUR+100.0%+2.4%0.0%
Peer median (excluding AVXL) —+100.0%+2.4%7.0%

Competitors are the stored peer set for AVXL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income(37.91M)(47.98M)(47.51M)(43M)(46.38M)
Depreciation & Amortization00000
Deferred Income Tax00000
Stock-Based Compensation8.23M18.38M16.37M9.44M11.55M
Change in Working Capital(706K)5.36M2.51M2.75M(4.22M)
Accounts Receivables(4.29M)5.94M484K260K1.64M
Inventory00000
Accounts Payables751K(914K)497K5.31M(5.38M)
Other Working Capital2.83M331K1.52M(2.81M)(478K)
Other Non-Cash Items00845K00
Operating Cash Flow(30.38M)(24.24M)(27.79M)(30.81M)(39.04M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment00000
Common Stock Issued153.22M22M29.65M11.98M12.14M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities24K(707K)29.65M11.98M(2.71M)
Financing Cash Flow153.24M21.29M29.65M11.98M9.43M
Effect of Forex Changes00000
Net Change in Cash122.86M(2.95M)1.87M(18.84M)(29.61M)
Free Cash Flow(30.38M)(24.24M)(27.79M)(30.81M)(39.04M)

Anavex Life Sciences Corp.

NASDAQ:AVXL

Intrinsic Alpha fair value

Locked

Current Price

$0.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.